New Diabetes Drug Outperformed Tirzepatide in Clinical Trial
Adults with type 2 diabetes saw greater weight loss with CagriSema than with a 5 mg dose of tirzepatide in recent tests.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you trust that newer weight-loss medications generally offer significant benefits over existing treatment options?
In a phase 3 trial known as REIMAGINE 5, the experimental drug CagriSema led to a 12.4% average weight reduction compared to 9.1% for tirzepatide among adults with type 2 diabetes. This study assessed outcomes in patients who were inadequately controlled on metformin or an SGLT2 inhibitor.
Why it matters
The findings represent a potential shift in treatment options for individuals managing type 2 diabetes who also require weight management support. Understanding these comparative efficacy results may help patients and their clinicians weigh emerging therapeutic choices.
In the REIMAGINE 5 phase 3 trial, 1.0 mg/1.0 mg CagriSema was compared against 5 mg tirzepatide over 60 weeks in adults with type 2 diabetes. While CagriSema showed superior weight loss, it demonstrated noninferiority regarding glycated hemoglobin A reduction.
The players
Novo Nordisk
A global pharmaceutical company specializing in diabetes care and obesity treatments.
The details
CagriSema is an experimental treatment that combines two active components to manage both blood glucose levels and weight. In the REIMAGINE 5 trial, participants taking 1.0 mg/1.0 mg of the drug achieved a 12.4% weight loss, compared to 9.1% in those taking 5 mg of tirzepatide. Separately, the REDEFINE 9 study demonstrated that CagriSema could produce a 21.0% weight reduction over 68 weeks, whereas a placebo group showed a 2.0% reduction.
Timeline
December 2025: Novo Nordisk filed a new drug application with the FDA.
September 21, 2026: Topline phase 3 trial results were announced.
Q4 2026: The FDA is expected to reach a decision regarding weight management applications.
Health Landscape
This development sits within the broader evolution of the GLP-1 receptor agonist research pipeline, which continues to refine treatments for metabolic disease. These results underscore a shift in therapeutic goals, prioritizing more effective weight reduction alongside standard glucose management.
These findings are strictly for informational purposes and should not prompt any changes to your current diabetes management plan. If you are interested in how emerging clinical trial data might eventually impact your care, discuss these developments with your primary physician.
The takeaway
CagriSema demonstrated statistically significant weight loss advantages over tirzepatide in a recent comparative study for diabetes patients. Always consult your endocrinologist or primary care physician to understand if new clinical findings or emerging therapies are relevant to your long-term health.
What happens next
An FDA regulatory decision regarding the weight management application for CagriSema is anticipated in the fourth quarter of 2026.
Further reading
For broader context on current approaches for managing glucose and metabolic health, visit the Diabetes section.
Live Poll
Do you trust that newer weight-loss medications generally offer significant benefits over existing treatment options?
